Galectin Narrows Q3 Loss to $3.6M as Phase 3 Protocol Sits With FDA
GALT sits 53% above its 52-week low of $2.025.
Summary
Galectin posted a Q3 net loss of $3.6 million, or $0.04 a share, versus $8.2 million, or $0.13 a share a year ago — the improvement driven mainly by lower interest expense and a $594 thousand derivative gain rather than operations. Cash stood at $11.7 million on September 30, with $10 million still available on the chairman's line of credit, which management says funds operations through June 2027. The 10-Q filed today carries a going-concern flag, so the runway statement is the number that matters most here. On the pipeline, the registrational Phase 3 protocol for belapectin in MASH cirrhosis with portal hypertension went to the FDA in Q3 after alignment on the composite liver outcome endpoint, blinded central variceal review, and a single 2 mg/kg LBM dose. New AASLD data showed a 15.9% placebo-adjusted improvement (p=0.04) in ANTICIPATE-NASH predicted CSPH risk at 18 months. Additional Phase 3 detail is expected at the December 3, 2026 annual stockholders' meeting, where shareholders also vote on a 100 million share authorized-increase proposal.
At the time of this announcement, GALT was trading at $3.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $307.6M. The 52-week trading range was $2.03 to $7.13. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.